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Galectin-1, a member of the S-type mammalian lectin family
is characterized by high affinity for β-galactoside on complex
glycoconjugates and by a highly conserved carbohydrate
recognition domain (CRD). Galectin-1 induces apoptosis of
immature cortical thymocytes, activated peripheral T lym-
phocytes and T leukemia cell lines. According to this func-
tion, galectin-1 is a potential valuable therapeutic agent in
autoimmune and inflammatory diseases. In spite of the
increasing interest, the molecular mechanism of the apoptotic
process is not well understood yet.
In the present study, we examined the possible involve-
ment of protein kinase C (PKC) and ceramide in apoptosis
induced by galectin-1. Recently, we showed that p56lck, the
non-receptor tyrosine kinase is involved in the galectin-1
triggered apoptosis. The literature data indicated that ce-
ramide, an apoptotic lipid second messenger also dependent
on the presence of functional lck. Upon this finding we have
been analysing whether galectin-1 acts through the ceramide
mediated apoptotic pathway. The latter was analysed by
exogenously added C6-ceramide, as a model. We found that:
1) Phorbol 12,13-dibutyrate (PDBu) inhibited the galectin-1
induced apoptosis by 50-100%. Since PDBu directly ac-
tivates PKC, we suggest that PKC activation counteracts
galectin-1-mediated apoptosis similarly to that induced by
ceramide. 2) A caspase-8 inhibitor did not affect the apop-
tosis either induced by galectin-1 or ceramide. In order to
clearly determine whether caspase-8 is requisite for galectin-
1 mediated apoptosis we compared the sensitivity of the wild
type and the caspase-8 deficient (J-C8mut) Jurkat cells. Both
cell lines were similarly sensitive to galectin-1 and ceramide
but the caspase 8 mutant was resistant to apoptosis initiated
via the TNF receptor. 3. To gain a direct evidence for the role
of the ceramide pathway in this process we used fumonisin
B1 a specific inhibitor of ceramide synthesis. This drug did
not inhibit the effect of galectin-1 indicating that production
of ceramide upon galectin-1 stimulation did not occur
through the synthetic route. Further we studied whether the
catabolic production of ceramide is involved in galectin-1
induced apoptosis. For this purpose we used another inhibitor
of ceramide-mediated apoptosis, sphingosine-1 phosphate
(S1P). S1P inhibited the galectin-1 or ceramide induced
apoptosis similarly. Thus, S1P, likely generated via PKC-
mediated activation of sphingosine kinase, downregulates the
galectin-1 apoptotic pathway. Taken together, our results
strongly suggest that galectin-1 induced apoptosis is me-
diated by the intracellular ceramide level, leading to the
activation of a caspase cascade.
